Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.

Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group.

Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30.

PMID:
30377778
2.

Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.

Sapp JL, Parkash R, Wells GA, Yetisir E, Gardner MJ, Healey JS, Thibault B, Sterns LD, Birnie D, Nery PB, Sivakumaran S, Essebag V, Dorian P, Tang AS.

Circ Arrhythm Electrophysiol. 2017 Mar;10(3). pii: e004875. doi: 10.1161/CIRCEP.116.004875.

PMID:
28292754
3.

Frequency and Outcomes of Postrandomization Atrial Tachyarrhythmias in the Resynchronization/Defibrillation in Ambulatory Heart Failure Trial.

Wilton SB, Exner DV, Wyse DG, Yetisir E, Wells G, Tang AS, Healey JS.

Circ Arrhythm Electrophysiol. 2016 May;9(5). pii: e003807. doi: 10.1161/CIRCEP.115.003807.

PMID:
27162033
4.

Incidence, predictors, and procedural results of upgrade to resynchronization therapy: the RAFT upgrade substudy.

Essebag V, Joza J, Birnie DH, Sapp JL, Sterns LD, Philippon F, Yee R, Crystal E, Kus T, Rinne C, Healey JS, Sami M, Thibault B, Exner DV, Coutu B, Simpson CS, Wulffhart Z, Yetisir E, Wells G, Tang AS.

Circ Arrhythm Electrophysiol. 2015 Feb;8(1):152-8. doi: 10.1161/CIRCEP.114.001997. Epub 2014 Nov 23.

PMID:
25417892
5.

Spatial abilities of medical graduates and choice of residency programs.

Langlois J, Wells GA, Lecourtois M, Bergeron G, Yetisir E, Martin M.

Anat Sci Educ. 2015 Mar-Apr;8(2):111-9. doi: 10.1002/ase.1453. Epub 2014 Jun 20.

PMID:
24953052
6.

Impact of cardiac resynchronization therapy on hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure trial.

Gillis AM, Kerr CR, Philippon F, Newton G, Talajic M, Froeschl M, Froeschl S, Swiggum E, Yetisir E, Wells GA, Tang AS.

Circulation. 2014 May 20;129(20):2021-30. doi: 10.1161/CIRCULATIONAHA.112.000417. Epub 2014 Mar 7.

PMID:
24610807
7.

Left ventricular lead position and outcomes in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).

Wilton SB, Exner DV, Healey JS, Birnie D, Arnold MO, Sapp JL, Thibault B, Simpson CS, Tung S, Crystal E, Sivakumaran S, Khaykin Y, Yetisir E, Wells G, Tang AS; RAFT Investigators.

Can J Cardiol. 2014 Apr;30(4):413-9. doi: 10.1016/j.cjca.2013.10.009. Epub 2013 Oct 18.

PMID:
24561009
8.

Sex differences in spatial abilities of medical graduates entering residency programs.

Langlois J, Wells GA, Lecourtois M, Bergeron G, Yetisir E, Martin M.

Anat Sci Educ. 2013 Nov-Dec;6(6):368-75. doi: 10.1002/ase.1360. Epub 2013 Apr 2.

PMID:
23554271
9.

Sprint Fidelis lead fractures in patients with cardiac resynchronization therapy devices: insight from the Resynchronization/Defibrillation for Ambulatory Heart Failure (RAFT) study.

Parkash R, Thibault B, Sterns L, Sapp J, Krahn A, Talajic M, Luce M, Yetisir E, Theoret-Patrick P, Wells G, Tang A.

Circulation. 2012 Dec 18;126(25):2928-34. doi: 10.1161/CIRCULATIONAHA.112.132100. Epub 2012 Nov 16.

PMID:
23159551
10.

Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).

Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM, Sivakumaran S, Yetisir E, Wells GA, Tang AS; RAFT Investigators.

Circ Heart Fail. 2012 Sep 1;5(5):566-70. Epub 2012 Aug 14.

PMID:
22896584
11.

Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials.

Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S, Peterson J, Yetisir E, Theoret-Patrick P, Luce M, Tang AS.

CMAJ. 2011 Mar 8;183(4):421-9. doi: 10.1503/cmaj.101685. Epub 2011 Jan 31.

12.

Spatial abilities in an elective course of applied anatomy after a problem-based learning curriculum.

Langlois J, Wells GA, Lecourtois M, Bergeron G, Yetisir E, Martin M.

Anat Sci Educ. 2009 May-Jun;2(3):107-12. doi: 10.1002/ase.84.

PMID:
19496160
13.

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.

Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD.

Osteoporos Int. 2009 Feb;20(2):291-7. doi: 10.1007/s00198-008-0653-8. Epub 2008 Jul 29.

PMID:
18663402
14.

Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury.

McIntyre LA, Fergusson DA, Hutchison JS, Pagliarello G, Marshall JC, Yetisir E, Hare GM, Hébert PC.

Neurocrit Care. 2006;5(1):4-9.

PMID:
16960287
15.

Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.

Van Der Jagt R, Robinson KS, Belch A, Yetisir E, Wells G, Larratt L, Shustik C, Gluck S, Stewart K, Sheridan D; Canadian Leukemia Studies Group.

Leuk Lymphoma. 2006 Apr;47(4):697-706.

PMID:
16690529
16.

Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol.

Podymow T, Turnbull J, Coyle D, Yetisir E, Wells G.

CMAJ. 2006 Jan 3;174(1):45-9.

17.

Prostaglandin E vaginal gel to treat dystocia in spontaneous labour: a multicentre randomised placebo-controlled trial.

Oppenheimer LW, Labrecque M, Wells G, Bland ES, Fraser WD, Eason E, Brisson-Carroll G, Yetisir E.

BJOG. 2005 May;112(5):612-8.

18.

Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?

McIntyre L, Hebert PC, Wells G, Fergusson D, Marshall J, Yetisir E, Blajchman MJ; Canadian Critical Care Trials Group.

J Trauma. 2004 Sep;57(3):563-8; discussion 568.

PMID:
15454803
19.

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.

Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G.

N Engl J Med. 2003 Jun 26;348(26):2618-25.

20.

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article].

Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R.

Neurology. 2001 Dec;57(12 Suppl 5):S31-5. No abstract available.

PMID:
11902593
21.

Do blood transfusions improve outcomes related to mechanical ventilation?

Hébert PC, Blajchman MA, Cook DJ, Yetisir E, Wells G, Marshall J, Schweitzer I; Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group.

Chest. 2001 Jun;119(6):1850-7.

PMID:
11399714
22.

Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?

Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I; Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group.

Crit Care Med. 2001 Feb;29(2):227-34.

PMID:
11246298
23.

A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial.

Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E, Hart RG.

JAMA. 1999 Aug 25;282(8):737-43.

PMID:
10463708
24.

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E.

N Engl J Med. 1999 Feb 11;340(6):409-17. Erratum in: N Engl J Med 1999 Apr 1;340(13):1056.

26.

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.

Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R.

Neurology. 1994 Jan;44(1):16-20.

PMID:
8290055
27.

Cyclophosphamide and plasma exchange in multiple sclerosis.

Noseworthy JH, Vandervoort MK, Penman M, Ebers G, Shumak K, Seland TP, Roberts R, Yetisir E, Gent M, Taylor DW.

Lancet. 1991 Jun 22;337(8756):1540-1. No abstract available.

PMID:
1675382

Supplemental Content

Loading ...
Support Center